Mycobacterium africanum
Mycobacterium africanum is a type of bacteria that is part of the Mycobacterium tuberculosis complex (MTBC). It is one of the causative agents of tuberculosis (TB) in humans, particularly in West Africa.
History[edit]
Mycobacterium africanum was first described in 1968 by a French scientist named Castets. It was isolated from the sputum of a Senegalese patient who had pulmonary tuberculosis. The bacterium was named "africanum" due to its prevalence in Africa.
Characteristics[edit]
Mycobacterium africanum is a slow-growing, acid-fast bacterium. It shares many characteristics with other members of the MTBC, including Mycobacterium tuberculosis and Mycobacterium bovis. However, it has some unique genetic and phenotypic characteristics that distinguish it from other MTBC members.
Epidemiology[edit]
Mycobacterium africanum is responsible for a significant proportion of TB cases in West Africa. It is less common in other parts of the world. The reasons for this geographical restriction are not fully understood, but it is thought to be related to both host and bacterial factors.
Clinical significance[edit]
Infection with Mycobacterium africanum can lead to the development of TB. The clinical presentation and treatment of TB caused by Mycobacterium africanum is similar to that of TB caused by Mycobacterium tuberculosis. However, some studies suggest that Mycobacterium africanum may be associated with a slower disease progression and a lower transmission rate than Mycobacterium tuberculosis.
Research[edit]
Research on Mycobacterium africanum is ongoing to better understand its biology, epidemiology, and pathogenesis. This research is important for the development of new strategies for the prevention and treatment of TB.
See also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
